Subthreshold Diode Micropulse Photocoagulation for the Treatment of Chronic Central Serous Chorioretinopathy with Juxtafoveal Leakage

Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy

“…More than 60% of our patients had a disease duration of 41 year. Moreover, some studies show a slightly higher increase in BCVA after SML 17,23 and PDT 13,15,29 compared with our results. This could be attributed to the relatively low BCVA in our patients at baseline.…”

“…The idea is that retinal damage is not needed to acquire a therapeutic effect. 16 Studies with a 810 nm micropulse diode laser [17][18][19][20][21] and a 577nm micropulse laser 22,23 showed efficacy in CSC patients with subfoveal and extrafoveal leakage sites.…”

Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome

“…The SM diode (810 nm) laser has been previously used in the management of CSCR, [16][17][18] whereas there are only few anecdotal reports (http://bmctoday.net/ retinatoday/2010/02/article.asp?f=a-new-treatmentfor-chronic-central-serous-retinopathy) on the use of the SM yellow (577 nm) laser so far. The yellow (577 nm) wavelength occurs outside the absorption spectrum of retinal xanthophylls, potentially allowing for treatment close to the fovea.…”

Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy

“…4 Choroidal neovascularization (CNV) is also known as a serious complication of LP. [5][6][7][8] Recently, photodynamic therapy (PDT) with verteporfin has been shown to be effective in reducing SRF and improving visual acuity for chronic CSC. [9][10][11][12] However, post-PDT complications such as secondary CNV, pigmentary changes of the retinal pigment epithelium (RPE), and persistent choriocapillaris hypoperfusion have been reported.…”